Drug Profile
sNN 0029
Alternative Names: rhVEGF165 - Newron Pharmaceuticals; sNN-0029; Telbermin - Newron PharmaceuticalsLatest Information Update: 10 Feb 2016
Price :
$50
*
At a glance
- Originator NeuroNova AB
- Developer Newron Pharmaceuticals
- Class Growth factors
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 26 Jan 2016 Newron terminates a phase I/II trial in Amyotrophic lateral sclerosis in Belgium (NCT01384162)
- 26 Jan 2016 Newron terminates two phase I trials in Amyotrophic lateral sclerosis in Belgium and the Netherlands (NCT01999803; NCT02269436)
- 31 Oct 2015 Discontinued - Phase-II for Amyotrophic lateral sclerosis in Belgium (Intracerebral)